{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:56:14Z","timestamp":1790776574608,"version":"4.1.0"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Recipients of HIV pre-exposure prophylaxis (PrEP) experience higher rates of gonorrhea and chlamydia diagnoses than non-recipients. However, it is unclear if these observations reflect a causal relationship between PrEP initiation and acquisition of sexually transmitted infections (i.e., behavioral \u201crisk compensation\u201d) or a diagnostic bias related to PrEP recipients screening more frequently than non-recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a self-controlled case series study comparing rates of gonorrhea and chlamydia diagnoses after versus before PrEP initiation among commercially-insured US males in the Merative MarketScan\u00ae Research Databases (2016\u20132019). We compared matched incidence rate ratio (IRR) estimates after versus before PrEP initiation to model-based expectations under a null hypothesis of no change in infection risk. We derived null expectations via a mathematical model reflecting changes in screening after PrEP initiation, estimating parameters under a Bayesian framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Individuals experienced increased rates of gonorrhea (IRR=3.47 [95% confidence interval: 2.57-4.72]) and chlamydia (IRR=3.59 [2.50-5.27]) diagnoses after PrEP initiation, with IRR estimates differing by anatomical site (IRR=1.23 [0.71-2.13] and 5.98 [3.63-10.29] for urogenital and extragenital diagnoses of either infection, respectively). After accounting for increased rates of screening after PrEP initiation, rates of gonorrhea and chlamydia diagnoses only modestly exceeded expectations under the null hypothesis of no change in infection risk (8-14% greater-than-expected rates of gonorrhea and chlamydia diagnoses, respectively). Overall, we estimated that 80-81% of observed increases in rates of gonorrhea and chlamydia diagnoses after PrEP initiation, respectively, were attributable to increases in asymptomatic screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings suggest higher-frequency asymptomatic screening, rather than behavioral risk compensation, may account for increased rates of gonorrhea and chlamydia diagnoses after PrEP initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ede.0000000000002052","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:03:29Z","timestamp":1790773409000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced screening and bacterial sexually-transmitted infection diagnoses after HIV pre-exposure prophylaxis initiation"],"prefix":"10.1097","author":[{"given":"Anna M.","family":"Parker","sequence":"first","affiliation":[{"name":". Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel M.","family":"Jenness","sequence":"additional","affiliation":[{"name":". Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia 30322, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Singer","sequence":"additional","affiliation":[{"name":". Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Chang","sequence":"additional","affiliation":[{"name":". Department of Infectious Diseases, Los Angeles Medical Center, Southern California Permanente Medical Group, Los Angeles, California, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia J.","family":"Bruxvoort","sequence":"additional","affiliation":[{"name":". Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 35233, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Lewnard","sequence":"additional","affiliation":[{"name":". Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States"},{"name":". Center for Computational Biology, College of Computing, Data Science, and Society, University of California, Berkeley, Berkeley, California 94720, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,30]]},"container-title":["Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/EDE.0000000000002052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:03:30Z","timestamp":1790773410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/EDE.0000000000002052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1097\/ede.0000000000002052","relation":{},"ISSN":["1044-3983","1531-5487"],"issn-type":[{"value":"1044-3983","type":"print"},{"value":"1531-5487","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}